Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase II Trial of Single Agent VELCADE (bortezomib) in patients with previously untreated multiple myeloma

Phase II Trial of Single Agent VELCADE (bortezomib) in patients with previously untreated multiple myeloma. American Society for Hematology 46th Annual Meeting. 2004.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.